First targeted therapy for cholangiocarcinoma shows clinical benefit in phase III trial

New data have shown for the first time that targeted therapy can improve the outcome of patients diagnosed with advanced cholangiocarcinoma. Cholangiocarcinoma is a subtype of bile duct cancer with aggressive behavior and poor prognosis. Despite the low incidence, most patients die from the disease and therefore new effective therapies are urgently needed.